Pancreatic Cancer Research

ResearcherTianjin UniversityActive in the last 2 years

Guangbo Kang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5353-9788; OpenAlex author ID A5016360793, A5135856809. Sources: OpenAlex.

Their work

Papers
2 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
4
Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

  1. Integrative multi-omics analysis identifies ATAD1 as a potential regulator of metastasis in pancreatic cancer. First author DOI 10.1038/s41598-026-52051-3↗
  2. VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer in vivo. Co-author DOI 10.20892/j.issn.2095-3941.2020.0568↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Feng Gao · 1 shared paper, 2026 · strength 0.36
  2. Yi Zhang · 1 shared paper, 2026 · strength 0.36
  3. He Huang · 1 shared paper, 2021 · strength 0.13
  4. He Ren · 1 shared paper, 2021 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.